INTRAVESICAL EVANS BACILLE CALMETTE-GUERIN FOR CARCINOMA IN-SITU OF THE URINARY-BLADDER

Objective To study the long-term results of a single 8 week course of intravesical Evans bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the urinary bladder. Patients and methods This study reports on 43 patients who each received a single 8 week course of intravesical BCG. Results In spite of the good initial complete response rate of 70%, the long-term follow-up was disappointing with half the patients either having recurrence or progression of their disease by 2 years. The patients had a close follow-up protocol with early radical treatment when disease progressed. The cause specific survival at 5 years was 70%. Conclusion We feel that similar future treatment protocols without maintenance treatment are not justified.